View Older Stories View More Recent Stories

Dec 17, 2018 04:10PM Emergent BioSolutions Receives Health Canada Approval of BioThrax® (Anthrax Vaccine Adsorbed)
Nov 19, 2018 04:22PM Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus
Nov 19, 2018 04:22PM Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus
Nov 19, 2018 04:21PM Emergent Bio (EBS) announced positive interim results for Phase 1 study evaluating VLA1601 vaccine candidate against Zika
Nov 19, 2018 04:16PM EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS
Nov 6, 2018 07:00AM Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
Nov 6, 2018 07:00AM Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
Nov 1, 2018 04:30PM Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018
Nov 1, 2018 04:30PM Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018
Oct 24, 2018 02:30PM Emergent BioSolutions to Offer All Public Libraries and YMCAs in the U.S. Free Opioid Awareness Education and NARCAN® (naloxone HCl) Nasal Spray
Oct 24, 2018 02:30PM Emergent BioSolutions to Offer All Public Libraries and YMCAs in the U.S. Free Opioid Awareness Education and NARCAN® (naloxone HCl) Nasal Spray
Oct 15, 2018 04:30PM Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan® (Naloxone HCI) Nasal Spray
Oct 15, 2018 04:30PM Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan® (Naloxone HCI) Nasal Spray
Oct 11, 2018 06:30AM Emergent BioSolutions to Release Third Quarter 2018 Financial Results and Conduct a Conference Call on November 1, 2018
Oct 11, 2018 06:30AM Emergent BioSolutions to Release Third Quarter 2018 Financial Results and Conduct a Conference Call on November 1, 2018
Oct 4, 2018 06:27PM Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax
Oct 4, 2018 06:27PM Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax
Aug 28, 2018 04:31PM Emergent BioSolutions Joins Effort to Combat National Public Health Threat From Opioid Overdose Through Acquisition of Adapt Pharma and Its Flagship Product NARCAN® (naloxone HCl) Nasal Spray
Aug 28, 2018 04:31PM Emergent BioSolutions Joins Effort to Combat National Public Health Threat From Opioid Overdose Through Acquisition of Adapt Pharma and Its Flagship Product NARCAN® (naloxone HCl) Nasal Spray
Aug 17, 2018 07:00AM Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
Aug 17, 2018 07:00AM Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
Aug 16, 2018 06:23AM Emergent BioSolutions (EBS) Secures Up to $36M in Collaboration with Profectus BioSciences from CEPI to Develop Lassa Virus Vaccine
Aug 16, 2018 06:15AM CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
Aug 16, 2018 06:15AM CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
Aug 9, 2018 06:30AM Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
Aug 9, 2018 06:30AM Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
Aug 2, 2018 04:30PM Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018
Aug 2, 2018 04:30PM Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018
Jul 31, 2018 04:55PM Emergent BioSolutions (EBS) Commences Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic
Jul 31, 2018 04:30PM Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic
Jul 31, 2018 04:30PM Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic
Jul 18, 2018 04:30PM Emergent BioSolutions to Release Second Quarter 2018 Financial Results and Conduct a Conference Call on August 2, 2018
Jul 18, 2018 04:30PM Emergent BioSolutions to Release Second Quarter 2018 Financial Results and Conduct a Conference Call on August 2, 2018
Jun 8, 2018 06:30AM Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
Jun 8, 2018 06:30AM Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
Jun 7, 2018 06:30AM Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility
Jun 7, 2018 06:30AM Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility
May 24, 2018 06:16AM Emergent BioSolutions (EBS) in Collanoration with Profectus BioSciences Inc. Secures $25M Contract from CEPI to Develop Nipah Virus Vaccine
May 24, 2018 06:11AM CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine
May 24, 2018 06:11AM CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine
May 10, 2018 04:50PM Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available
May 10, 2018 04:50PM Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available
May 3, 2018 04:30PM Emergent BioSolutions Reports First Quarter 2018 Financial Results
May 3, 2018 04:30PM Emergent BioSolutions Reports First Quarter 2018 Financial Results
Apr 19, 2018 06:30AM Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
Apr 19, 2018 06:30AM Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
Apr 12, 2018 06:30AM Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries
Apr 12, 2018 06:30AM Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries
Apr 12, 2018 06:30AM Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries
Mar 26, 2018 04:30PM Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy
View More Recent Stories View Older Stories